Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rani Therapeutics Holdings (RANI) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Rani Therapeutics Holdings (RANI) over the last 6 years, with Q3 2025 value amounting to $46.4 million.

  • Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) rose 6106.26% to $46.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $46.4 million, marking a year-over-year increase of 6106.26%. This contributed to the annual value of $28476.0 for FY2024, which is 1164.87% up from last year.
  • Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) amounted to $46.4 million in Q3 2025, which was up 6106.26% from $36.5 million recorded in Q2 2025.
  • Over the past 5 years, Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) peaked at $46.9 million during Q2 2021, and registered a low of $19534.0 during Q4 2021.
  • In the last 5 years, Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) had a median value of $25.3 million in 2023 and averaged $22.8 million.
  • In the last 5 years, Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) tumbled by 4803.21% in 2022 and then surged by 6106.26% in 2025.
  • Quarter analysis of 5 years shows Rani Therapeutics Holdings' Shares Outstanding (Weighted Average) stood at $19534.0 in 2021, then grew by 21.93% to $23817.0 in 2022, then rose by 7.09% to $25505.0 in 2023, then grew by 11.65% to $28476.0 in 2024, then soared by 162998.75% to $46.4 million in 2025.
  • Its Shares Outstanding (Weighted Average) stands at $46.4 million for Q3 2025, versus $36.5 million for Q2 2025 and $33.4 million for Q1 2025.